A Study of Effects of Selpercatinib in Hepatically Impaired Participants and Healthy Participants

Clinical trial NCT05436912 · COMPLETED

Trial details

NCT number: NCT05436912
Sponsor: Eli Lilly and Company
Status: COMPLETED
Phase: Phase 1
Study type: INTERVENTIONAL

Healthy Hepatic Impairment

Start date: 2018-12-10
Primary completion: 2019-10-04
Enrollment: 36

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.